we did do a lower dose for three months as well and there we saw increases in lifespan in both males and females roughly the same magnitude
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
we did do a lower dose for three months as well and there we saw increases in lifespan in both males and females roughly the same magnitude
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
as you go higher in dose so 3 times higher than what they originally tested the females still live a little bit longer but the difference between males and females the gap has closed quite a bit so I think that females for whatever reason at a given concentration of rapamycin are just more affected by that amount of the drug
one school of thought is that female mice at least we don't know if the is true in any other organism female mice are more sensitive to rapamycin and that could either be that they don't clear the drug as quickly or that for whatever reason and female mice the same amount of rapamycin has a greater emmett or inhibitory effect but that's one school of thought and I kind of think that's right
so I think that females for whatever reason at a given concentration of rapamycin are just more affected by that amount
my guess is that because we push the dose so high we might have actually taken it too far in the female so one school of thought is that female mice at least we don't know if this is true in any other organism female mice are more sensitive to rapamycin and that could either be that they don't clear the drug as quickly or that for whatever reason and female mice the same amount of rapamycin has a greater mTOR inhibitor effect but that's one school of thought and I kind of think that's right
so I think that females for whatever reason at a given concentration of rapamycin are just more affected by that amount of the drug
again females had an advantage with rapamycin but both of these numbers are really quite impressive
the rapamycin blood content in the female mice was two or three times higher than it was in the male mice so it was higher and stayed up longer
i think it's more about effective concentration than it is a male versus female um truly sex-specific response
the Texas group showed that the blood concentrations are three-fold higher in females than in males
for instance many of our papers we published I think 12 papers now on Rapa and almost always Rapa has been giving a larger percentage increase in females than in males well um the Texas group showed that the blood concentrations are three-fold higher in females than in males we haven't proven that that's why the females live long ER or have a greater percentage increase but it's certainly very plausible
in the highest dose that anybody has used which is not in the ITP but um um in another study males had a big effect and females had no effect so the idea is maybe you've over overdosed the females at that stage
you know in rapy the sex bias is very in in longevity at least is very dose dependent at the lowest they' done the females live substantially longer than the or put it this way the effect of substantially bigger in females than in males and that difference gradually goes away as you get it to a higher and higher dose and in the highest dose that anybody has used which is not in the ITP but um um in another study males had a big effect and females had no effect
Do you recall that in the ITP the females had a much higher plasma level than the males despite consuming the same amount and I I don't remember if Rich had an explanation for why that was the case
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.